vs

Side-by-side financial comparison of Moderna (MRNA) and RPM INTERNATIONAL INC (RPM). Click either name above to swap in a different company.

RPM INTERNATIONAL INC is the larger business by last-quarter revenue ($1.9B vs $1.0B, roughly 1.9× Moderna). RPM INTERNATIONAL INC runs the higher net margin — 8.4% vs -19.7%, a 28.1% gap on every dollar of revenue. On growth, RPM INTERNATIONAL INC posted the faster year-over-year revenue change (3.5% vs -45.4%). RPM INTERNATIONAL INC produced more free cash flow last quarter ($296.4M vs $-880.0M). Over the past eight quarters, RPM INTERNATIONAL INC's revenue compounded faster (12.0% CAGR vs -45.0%).

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

BVS Entertainment, Inc., formerly known as Saban Productions, Saban International and Saban Entertainment, is a subsidiary of the Walt Disney Company. Founded on April 24, 1980, as a music production company by Haim Saban and Shuki Levy, it slowly transitioned to or gravitated towards television production and distribution, where it is most known for producing and distributing children's programs for Fox Family/ABC Family and defunct channels Fox Kids and Jetix.

MRNA vs RPM — Head-to-Head

Bigger by revenue
RPM
RPM
1.9× larger
RPM
$1.9B
$1.0B
MRNA
Growing faster (revenue YoY)
RPM
RPM
+48.9% gap
RPM
3.5%
-45.4%
MRNA
Higher net margin
RPM
RPM
28.1% more per $
RPM
8.4%
-19.7%
MRNA
More free cash flow
RPM
RPM
$1.2B more FCF
RPM
$296.4M
$-880.0M
MRNA
Faster 2-yr revenue CAGR
RPM
RPM
Annualised
RPM
12.0%
-45.0%
MRNA

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
MRNA
MRNA
RPM
RPM
Revenue
$1.0B
$1.9B
Net Profit
$-200.0M
$161.2M
Gross Margin
79.6%
40.8%
Operating Margin
-25.6%
11.0%
Net Margin
-19.7%
8.4%
Revenue YoY
-45.4%
3.5%
Net Profit YoY
-1638.5%
-12.0%
EPS (diluted)
$-0.51
$1.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRNA
MRNA
RPM
RPM
Q4 25
$1.9B
Q3 25
$1.0B
$2.1B
Q2 25
$2.1B
Q1 25
$1.5B
Q4 24
$966.0M
$1.8B
Q3 24
$1.9B
$2.0B
Q2 24
$2.0B
Q1 24
$1.5B
Net Profit
MRNA
MRNA
RPM
RPM
Q4 25
$161.2M
Q3 25
$-200.0M
$227.6M
Q2 25
$225.8M
Q1 25
$52.0M
Q4 24
$-1.1B
$183.2M
Q3 24
$13.0M
$227.7M
Q2 24
$180.6M
Q1 24
$61.2M
Gross Margin
MRNA
MRNA
RPM
RPM
Q4 25
40.8%
Q3 25
79.6%
42.3%
Q2 25
42.4%
Q1 25
38.4%
Q4 24
23.5%
41.4%
Q3 24
72.4%
42.5%
Q2 24
41.4%
Q1 24
39.9%
Operating Margin
MRNA
MRNA
RPM
RPM
Q4 25
11.0%
Q3 25
-25.6%
14.1%
Q2 25
11.9%
Q1 25
2.8%
Q4 24
-129.0%
11.5%
Q3 24
-3.8%
14.8%
Q2 24
11.9%
Q1 24
5.5%
Net Margin
MRNA
MRNA
RPM
RPM
Q4 25
8.4%
Q3 25
-19.7%
10.8%
Q2 25
10.8%
Q1 25
3.5%
Q4 24
-115.9%
9.9%
Q3 24
0.7%
11.6%
Q2 24
9.0%
Q1 24
4.0%
EPS (diluted)
MRNA
MRNA
RPM
RPM
Q4 25
$1.26
Q3 25
$-0.51
$1.77
Q2 25
$1.76
Q1 25
$0.40
Q4 24
$-2.91
$1.42
Q3 24
$0.03
$1.77
Q2 24
$1.40
Q1 24
$0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRNA
MRNA
RPM
RPM
Cash + ST InvestmentsLiquidity on hand
$1.1B
$316.6M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$9.3B
$3.1B
Total Assets
$12.1B
$7.9B
Debt / EquityLower = less leverage
0.80×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRNA
MRNA
RPM
RPM
Q4 25
$316.6M
Q3 25
$1.1B
$297.1M
Q2 25
$302.1M
Q1 25
$241.9M
Q4 24
$1.9B
$268.7M
Q3 24
$1.6B
$231.6M
Q2 24
$237.4M
Q1 24
$248.9M
Total Debt
MRNA
MRNA
RPM
RPM
Q4 25
$2.5B
Q3 25
$2.7B
Q2 25
$2.6B
Q1 25
$2.1B
Q4 24
$2.0B
Q3 24
$2.0B
Q2 24
$2.0B
Q1 24
$2.2B
Stockholders' Equity
MRNA
MRNA
RPM
RPM
Q4 25
$3.1B
Q3 25
$9.3B
$3.1B
Q2 25
$2.9B
Q1 25
$2.7B
Q4 24
$10.9B
$2.7B
Q3 24
$11.9B
$2.6B
Q2 24
$2.5B
Q1 24
$2.3B
Total Assets
MRNA
MRNA
RPM
RPM
Q4 25
$7.9B
Q3 25
$12.1B
$7.9B
Q2 25
$7.8B
Q1 25
$6.6B
Q4 24
$14.1B
$6.7B
Q3 24
$15.8B
$6.6B
Q2 24
$6.6B
Q1 24
$6.4B
Debt / Equity
MRNA
MRNA
RPM
RPM
Q4 25
0.80×
Q3 25
0.87×
Q2 25
0.91×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.77×
Q2 24
0.79×
Q1 24
0.93×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRNA
MRNA
RPM
RPM
Operating Cash FlowLast quarter
$-847.0M
$345.7M
Free Cash FlowOCF − Capex
$-880.0M
$296.4M
FCF MarginFCF / Revenue
-86.6%
15.5%
Capex IntensityCapex / Revenue
3.2%
2.6%
Cash ConversionOCF / Net Profit
2.14×
TTM Free Cash FlowTrailing 4 quarters
$-1.9B
$582.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRNA
MRNA
RPM
RPM
Q4 25
$345.7M
Q3 25
$-847.0M
$237.5M
Q2 25
$149.2M
Q1 25
$91.5M
Q4 24
$825.0M
$279.4M
Q3 24
$-1.6B
$248.1M
Q2 24
$181.2M
Q1 24
$173.4M
Free Cash Flow
MRNA
MRNA
RPM
RPM
Q4 25
$296.4M
Q3 25
$-880.0M
$175.0M
Q2 25
$78.2M
Q1 25
$33.3M
Q4 24
$303.0M
$229.5M
Q3 24
$-1.7B
$197.3M
Q2 24
$105.3M
Q1 24
$124.6M
FCF Margin
MRNA
MRNA
RPM
RPM
Q4 25
15.5%
Q3 25
-86.6%
8.3%
Q2 25
3.8%
Q1 25
2.3%
Q4 24
31.4%
12.4%
Q3 24
-92.2%
10.0%
Q2 24
5.2%
Q1 24
8.2%
Capex Intensity
MRNA
MRNA
RPM
RPM
Q4 25
2.6%
Q3 25
3.2%
3.0%
Q2 25
3.4%
Q1 25
3.9%
Q4 24
54.0%
2.7%
Q3 24
8.1%
2.6%
Q2 24
3.8%
Q1 24
3.2%
Cash Conversion
MRNA
MRNA
RPM
RPM
Q4 25
2.14×
Q3 25
1.04×
Q2 25
0.66×
Q1 25
1.76×
Q4 24
1.53×
Q3 24
-120.46×
1.09×
Q2 24
1.00×
Q1 24
2.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

RPM
RPM

Construction Products Group Segment$737.4M39%
Consumer Segment$638.6M33%
Performance Coatings Group Segment$533.8M28%

Related Comparisons